Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence: ...

LNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Lantheus strengthens its radiopharmaceutical business with Evergreen and Life Molecular acquisitions, adding oncology and ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment ...

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.

On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $ ...

On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 ...